BIOLINERX LTD. Inactive Instrument
BioLineRX Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
IL0011015182
Biotechnology & Medical Research
| Sales 2024 * | 14.36M 5.4B | Sales 2025 * | 27.77M 10.44B | Capitalization | 52.76M 19.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -47M -17.67B | Net income 2025 * | -36M -13.53B | EV / Sales 2024 * | 3.67 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioLineRX Ltd.
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 62 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Michael Anghel
BRD | Director/Board Member | 85 | 10-08-31 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
